Role of Inhaled Nitric Oxide in Vascular Mechanics and Right Ventricular Function
Collapsed Lung, Hemodynamic Stability
About this trial
This is an interventional treatment trial for Collapsed Lung
Eligibility Criteria
Age > 18 years Under controlled mechanical ventilation in passive conditions Presence of postoperative lung collapse (confirmed by pulmonary echocardiography and Air test) Preoperative left ventricular ejection fraction (LVEF) ≥ 30%. Absence of hypovolemia: absence of "kissing" ventricles and/or collapsibility index of the superior vena cava < 20%. Stable spontaneous heart rhythm Postoperative hemodynamic stability: Mean arterial pressure (MAP) ≥ 60 mmHg Central venous pressure (CVP) ≥ 10 mmHg Heart rate (HR) ≤ 100 bpm without tachyarrhythmias Lactic acid ≤ 3 mmol/L Single vasopressor treatment Norepinephrine dose ≤ 0.2 μg/kg/min, without an increase ≥ 15% in the last 30 -minutes. Obtained informed consent
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
No Intervention
Experimental
Experimental
Standard treatment (CONT)
iNO 20-40 ppm
iNO 20 - 40 ppm + Lung recruitment (iNO-RM)
The patient will be managed according to the routine clinical protocol, homogenizing the interventions in both participating centers.
In this arm, inhaled nitric oxide therapy will be initiated at 20 ppm immediately after randomization and after initial data collection. The dose will be reassessed after the first 30 min and may be increased to a maximum of 40 ppm depending on the response observed in ventricular function.
After 30 min after initiation of nitric oxide therapy following randomization, once patient stability has been confirmed, a brief recruitment maneuver will be performed and the subsequent PEEP level will be individualized according to the best lung compliance. Ventilation will then continue with the standard baseline ventilator settings, but with the PEEP level individually optimized.